TY - JOUR
T1 - A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@)
T2 - Update 2020
AU - Ansotegui, Ignacio J.
AU - Melioli, Giovanni
AU - Canonica, Giorgio Walter
AU - Gómez, R. Maximiliano
AU - Jensen-Jarolim, Erika
AU - Ebisawa, Motohiro
AU - Luengo, Olga
AU - Caraballo, Luis
AU - Passalacqua, Giovanni
AU - Poulsen, Lars K.
AU - Savi, Eleonora
AU - Zuberbier, Torsten
AU - Villa, Elisa
AU - Oppenheimer, John
AU - Asero, Riccardo
AU - Bernstein, Jonathan
AU - Bousquet, Jean
AU - Cardona, Victoria
AU - Cox, Lindo
AU - Demoly, Pascal
AU - Ferreira, Fatima
AU - Giavina Bianchi, Pedro
AU - Gonzalez Diaz, Sandra
AU - Jakob, Thilo
AU - Kase Tanno, Luciana
AU - Kleine-Tebbe, Jorg
AU - Levin, Michael
AU - Martin, Bryan
AU - Matricardi, Paolo Maria
AU - Monge Ortega, Olga Patricia
AU - Morais Almeida, Mario
AU - Nunes, Carlos
AU - Ortega Martell, José Antonio
AU - Renz, Harald
AU - Rosário Filho, Nelson
AU - Rouadi, Philip
AU - Ruiba, Alessia
AU - Sampson, Hugh
AU - Sánchez Borges, Mario
AU - Scala, Enrico
AU - Schmid-Grendelmeier, Peter
AU - Senna, Gian Enrico
AU - Sisul, Juan Carlos
AU - Tang, Mimi L.K.
AU - Valenta, Rudolf
AU - van Hage, Marianne
AU - Wong, Gary W.K.
AU - Yáñez, Anahí
AU - Steering Committee Authors
AU - Review Panel Members
N1 - Publisher Copyright:
© 2019
PY - 2020
Y1 - 2020
N2 - Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@. PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, Hymenoptera allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies.
AB - Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@. PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, Hymenoptera allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies.
KW - Cross reactivity
KW - Diagnosis
KW - Molecular allergy
KW - Panallergen
KW - Specific IgE, PAMD@
U2 - 10.1016/j.waojou.2019.100091
DO - 10.1016/j.waojou.2019.100091
M3 - Journal article
AN - SCOPUS:85081214827
SN - 1939-4551
VL - 13
JO - World Allergy Organization Journal
JF - World Allergy Organization Journal
IS - 2
M1 - 100091
ER -